FindTrial
Sign In

SHR7280 tablets

DRUG4 trials

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

Conditions

Assisted ReproductionEndometriosisEndometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted ReproductionFemale Subjects Undergoing COH in ART to Prevent Early OvulationUterine FibroidsUterine Fibroids With Menorrhagia

Phase 1

A Clinical Study Evaluating the Relative Bioavailability of SHR7280 Dry Suspension and Tablets
CompletedNCT05868057
Jiangsu HengRui Medicine Co., Ltd.Endometriosis, Uterine Fibroids, Male Hormone-sensitive Prostate Cancer, Assisted Reproduction
Start: 2023-05-23End: 2023-10-20Updated: 2023-12-08
A Phase 1 Clinical Study to Evaluate the Effects of SHR7280 on the Pharmacokinetics of Midazolam, S-warfarin, Omeprazole, Digoxin, and Rosuvastatin in Healthy Subjects
CompletedNCT06949124
Jiangsu HengRui Medicine Co., Ltd.Assisted Reproduction, Endometriosis, Uterine Fibroids
Start: 2025-04-28End: 2025-06-05Updated: 2025-09-10

Phase 2

Identify Effective Doses of SHR7280 Tablets in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART)
CompletedNCT05082233
Jiangsu HengRui Medicine Co., Ltd.Female Subjects Undergoing COH in ART to Prevent Early Ovulation
Start: 2022-03-06End: 2023-08-03Updated: 2024-02-20
A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids
RecruitingNCT05442827
Jiangsu HengRui Medicine Co., Ltd.Uterine Fibroids With Menorrhagia
Start: 2022-09-10End: 2026-06-01Target: 357Updated: 2024-01-24

Related Papers

Relative Bioavailability of Single-Dose Oral Administration of Two SHR7280 Formulations (Dry Suspension and Tablets) in Healthy Chinese Volunteers.
2025-08-08
SHR7280, an oral gonadotropin-releasing hormone antagonist, for the prevention of premature luteinizing hormone surge in controlled ovarian hyperstimulation: a dose-finding, phase 2 trial
Human Reproduction2025-05-15